GlassScriptPhysician profile
Ricky Dean Tate
NPI 1861488017
$11,496.08
in general payments reported to CMS, 2019-2025
54 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,316 · 2020: $1,444 · 2021: $1,862 · 2022: $1,746 · 2023: $1,445 · 2024: $1,215 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,128.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,271.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,263.20 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,187.68 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $1,097.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $839.21 | 2021-2025 | Vraylar, Qulipta |
| Astellas Pharma US INC | $781.65 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $523.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $448.98 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $394.25 | 2019-2025 | Xifaxan, Relistor |
| Novo Nordisk INC | $350.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $325.84 | 2019-2024 | Verquvo, Belsomra |
| Sanofi-Aventis U.S. LLC | $318.50 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.08 | 2019-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $220.19 | 2023-2025 | Gemtesa |
| Daiichi Sankyo INC. | $211.51 | 2020-2024 | Injectafer |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricky Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.